Mode
Text Size
Log in / Sign up

Pilot study explores ketogenic diet effects on symptoms in adults with generalized myasthenia gravisKetogenic diet may improve daily function in myasthenia gravis

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider ketogenic diet as a potential adjunctive therapy for generalized MG, but await larger blinded trials.

This randomized, controlled, open-label pilot study investigated the impact of a ketogenic diet versus a habitual diet on clinical outcomes in adults with generalized myasthenia gravis. The primary focus was on changes in activities of daily living, alongside secondary measures including fatigue, quality of life, and specific biomarkers.

The trial observed moderate median improvements in daily living activities and fatigue scores for participants following the ketogenic diet compared to controls. While some biomarkers showed numerical decreases, others remained unchanged. Quality of life and symptom state scores remained stable in the intervention group but worsened in the control group.

The authors highlight several limitations, including the exploratory design, open-label nature, and small cohort size. They note that findings should be interpreted with caution and require confirmation in larger, blinded studies. No serious adverse events were reported, and the diet was deemed feasible and safe during the short follow-up period.

Given the pilot nature of the research, these results suggest a potential benefit but do not yet support routine adoption. Clinicians should view these data as preliminary evidence warranting further investigation rather than established treatment guidelines.

For people with myasthenia gravis, an autoimmune disease that weakens muscles, everyday tasks like lifting a cup or climbing stairs can be exhausting. Now, a small pilot study suggests that a ketogenic diet might help. The diet is high in fat and low in carbs, forcing the body to burn fat for fuel.

The study randomly assigned 41 adults with generalized MG to either a ketogenic diet or their usual eating habits for about 2.8 months. Those on the keto diet saw a moderate improvement in their MG-ADL score, which measures how well they can manage daily activities. They also had less fatigue and better scores on a standard muscle strength test.

Quality of life and symptom satisfaction stayed steady in the keto group while getting worse in the control group. The diet appeared safe and feasible, though the study was small and open-label, meaning everyone knew what they were eating. That can bias results. The researchers caution that these findings are preliminary and need confirmation in larger, blinded trials.

What this means for you:
A keto diet showed moderate benefits for daily function and fatigue in myasthenia gravis, but more research is needed.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up2.8 mo
PublishedMay 2026
View Original Abstract ↓
OBJECTIVE: Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by fluctuating weakness and disabling fatigue. This pilot study assessed the feasibility and explored potential clinical and immunological effects of a ketogenic diet (KD) in generalized MG. METHODS: In a randomized, controlled, open-label 12-week pilot study, adults with generalized MG were assigned to a KD (n = 20) or to continue their habitual diet (n = 21). The primary endpoint was change in Myasthenia Gravis-Activities of Daily Living (MG-ADL). Secondary outcomes included Quantitative Myasthenia Gravis score (QMG), MGFA class, Fatigue Severity Scale (FSS), Myasthenia Gravis Quality of Life (MG-QoL15r), Patient Acceptable Symptom State (PASS), serum calprotectin (sCLP), serum neurofilament light chain (sNfL), and T-cell subsets. Analyses were conducted descriptively using effect sizes and 95% confidence intervals. RESULTS: Numerical improvements were observed in the KD group compared to controls. MG-ADL decreased (median Δ -2; moderate effect size, 95% CI including zero). QMG improved (median Δ -3; effect size 1.29, 95% CI 0.55-2.02), and fatigue decreased (median Δ -7; effect size 1.19, 95% CI 0.45-1.91). MG-QoL15r and PASS remained stable in the intervention group but worsened in controls. sCLP showed a numerical decrease, while sNfL remained unchanged. Adherence, defined as study completion, was 75%. CONCLUSION: A ketogenic diet is feasible and safe. Numerical improvements in clinical outcomes, and exploratory immunological changes were observed. Given the exploratory design findings should be interpreted with caution and require confirmation in larger, blinded studies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.